Tidal Investments LLC Sells 28,619 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Tidal Investments LLC trimmed its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 67.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 13,856 shares of the company's stock after selling 28,619 shares during the period. Tidal Investments LLC's holdings in Teva Pharmaceutical Industries were worth $250,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the stock. Sanctuary Advisors LLC increased its holdings in shares of Teva Pharmaceutical Industries by 1.9% during the third quarter. Sanctuary Advisors LLC now owns 35,129 shares of the company's stock worth $601,000 after buying an additional 664 shares in the last quarter. Sequoia Financial Advisors LLC grew its position in Teva Pharmaceutical Industries by 0.7% during the 3rd quarter. Sequoia Financial Advisors LLC now owns 112,380 shares of the company's stock worth $2,025,000 after acquiring an additional 805 shares during the last quarter. Smithfield Trust Co raised its position in Teva Pharmaceutical Industries by 55.7% in the 3rd quarter. Smithfield Trust Co now owns 2,739 shares of the company's stock valued at $50,000 after purchasing an additional 980 shares during the last quarter. Signaturefd LLC raised its position in Teva Pharmaceutical Industries by 16.9% in the 3rd quarter. Signaturefd LLC now owns 7,583 shares of the company's stock valued at $137,000 after purchasing an additional 1,094 shares during the last quarter. Finally, Bridgewater Associates LP boosted its stake in Teva Pharmaceutical Industries by 5.2% in the third quarter. Bridgewater Associates LP now owns 23,222 shares of the company's stock worth $418,000 after purchasing an additional 1,144 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on TEVA shares. JPMorgan Chase & Co. raised their target price on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a "neutral" rating in a research note on Monday, October 21st. Barclays boosted their target price on shares of Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the stock an "overweight" rating in a research note on Wednesday, December 18th. StockNews.com lowered shares of Teva Pharmaceutical Industries from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, December 18th. Finally, UBS Group raised their price target on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a "buy" rating in a report on Tuesday, September 3rd. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $20.88.

Insider Transactions at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, EVP Christine Fox sold 19,388 shares of the company's stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total value of $327,075.56. Following the completion of the sale, the executive vice president now owns 44,104 shares of the company's stock, valued at approximately $744,034.48. This represents a 30.54 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Roberto Mignone sold 286,000 shares of Teva Pharmaceutical Industries stock in a transaction on Friday, December 20th. The stock was sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the transaction, the director now directly owns 695,000 shares in the company, valued at approximately $15,296,950. This represents a 29.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.55% of the stock is owned by corporate insiders.

Teva Pharmaceutical Industries Trading Up 0.9 %

Shares of TEVA traded up $0.20 on Thursday, reaching $22.62. 7,484,542 shares of the company's stock were exchanged, compared to its average volume of 9,422,448. The business has a 50 day moving average price of $18.06 and a two-hundred day moving average price of $17.64. Teva Pharmaceutical Industries Limited has a 12 month low of $10.39 and a 12 month high of $22.80. The stock has a market capitalization of $25.63 billion, a P/E ratio of -26.61, a price-to-earnings-growth ratio of 0.99 and a beta of 0.79. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.57.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.